Table 3 Description of non-serious adverse events
Ivermectin (N = 250) | Placebo (N = 251) | |
|---|---|---|
Non-serious adverse event, N (%) | 45 (18) | 53 (21.11) |
Perianal abscess, N (%) | 0 (0) | 1 (0.4) |
Anosmia, N (%) | 3 (1.2) | 1 (0.4) |
Asthenia, N (%) | 0 (0) | 1 (0.4) |
Headache, N (%) | 1 (0.4) | 5 (2) |
Diarrhea, N (%) | 6 (2.4) | 8 (3.2) |
Dysgeusia, N (%) | 1 (0.4) | 0 (0) |
Dyspnea, N (%) | 1 (0.4) | 3 (1.2) |
Back pain, N (%) | 0 (0) | 1 (0.4) |
Chest pain, N (%) | 1 (0.4) | 0 (0) |
Worsening muscle pain, N (%) | 1 (0.4) | 0 (0) |
Epistaxis, N (%) | 0 (0) | 1 (0.4) |
Fatigue, N (%) | 0 (0) | 1 (0.4) |
Fever, N (%) | 4 (1.6) | 4 (1.6) |
Stomach flu, N (%) | 0 (0) | 1 (0.4) |
Dizziness, N (%) | 1 (0.4) | 0 (0) |
Myalgia, N (%) | 3 (1.2) | 0 (0) |
Nauseas, N (%) | 1 (0.4) | 4 (1.6) |
Pneumonia, N (%) | 16 (6.4) | 8 (3.2) |
Odynophagia, N (%) | 0 (0) | 1 (0.4) |
Palpitations, N (%) | 1 (0.4) | 0 (0) |
Rash, N (%) | 0 (0) | 2 (0.8) |
Dry cough, N (%) | 0 (0) | 7 (2.8) |
Urticaria, N (%) | 1 (0.4) | 2 (0.8) |
Vomiting, N (%) | 0 (0) | 1 (0.4) |
Arthralgia, N (%) | 1 (0.4) | 0 (0) |
Sciatica, N (%) | 0 (0) | 1 (0.4) |
Progression of dyspnea, N (%) | 1 (0.4) | 0 (0) |
Abdominal pain, N (%) | 1 (0.4) | 0 (0) |
Foot trauma, N (%) | 1 (0.4) | 0 (0) |